$ALT
Altimmune Inc

2021 Q1 Form 10-Q Financial Statement

#000156459021028166 Filed on May 17, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $838.0K $2.210M
YoY Change -62.08% -25.23%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.820M $2.330M
YoY Change 63.95% 12.56%
% of Gross Profit
Research & Development $11.88M $7.188M
YoY Change 65.26% 123.38%
% of Gross Profit
Depreciation & Amortization $74.00K $73.36K
YoY Change 0.88% 19.71%
% of Gross Profit
Operating Expenses $15.70M $9.519M
YoY Change 64.92% 80.15%
Operating Profit -$14.86M -$7.307M
YoY Change 103.39% 213.79%
Interest Expense $12.00K $1.885K
YoY Change 536.6% 154.73%
% of Operating Profit
Other Income/Expense, Net -$3.000K $175.2K
YoY Change -101.71% -24.23%
Pretax Income -$14.86M -$7.132M
YoY Change 108.37% 240.03%
Income Tax $0.00 -$3.246M
% Of Pretax Income
Net Earnings -$14.86M -$3.886M
YoY Change 282.54% 85.27%
Net Earnings / Revenue -1773.75% -175.82%
Basic Earnings Per Share -$0.38
Diluted Earnings Per Share -$0.38 -$257.4K
COMMON SHARES
Basic Shares Outstanding 38.91M 15.36M
Diluted Shares Outstanding 38.91M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $226.5M $32.90M
YoY Change 588.45% -25.73%
Cash & Equivalents $150.0M $11.31M
Short-Term Investments $76.60M $21.60M
Other Short-Term Assets $6.000M $700.0K
YoY Change 757.14% -36.36%
Inventory
Prepaid Expenses
Receivables $4.800M $2.000M
Other Receivables $7.900M $4.000M
Total Short-Term Assets $245.2M $39.60M
YoY Change 519.19% -19.86%
LONG-TERM ASSETS
Property, Plant & Equipment $6.100M $1.700M
YoY Change 258.82% 32.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K
YoY Change 0.0% -41.14%
Total Long-Term Assets $19.10M $14.60M
YoY Change 30.82% -8.52%
TOTAL ASSETS
Total Short-Term Assets $245.2M $39.60M
Total Long-Term Assets $19.10M $14.60M
Total Assets $264.3M $54.20M
YoY Change 387.64% -17.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $900.0K
YoY Change -55.56% 6000.45%
Accrued Expenses $9.406M $5.116M
YoY Change 83.86% 48.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.800M $6.000M
YoY Change 63.33% 63.2%
LONG-TERM LIABILITIES
Long-Term Debt $1.719M $1.791M
YoY Change -4.01% -22.69%
Other Long-Term Liabilities $95.38K $115.2K
YoY Change -17.22% -51.0%
Total Long-Term Liabilities $1.815M $1.906M
YoY Change -4.8% -25.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.800M $6.000M
Total Long-Term Liabilities $1.815M $1.906M
Total Liabilities $17.80M $12.30M
YoY Change 44.72% 103.25%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $246.4M $41.90M
YoY Change
Total Liabilities & Shareholders Equity $264.3M $54.20M
YoY Change 387.64% -17.09%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$14.86M -$3.886M
YoY Change 282.54% 85.27%
Depreciation, Depletion And Amortization $74.00K $73.36K
YoY Change 0.88% 19.71%
Cash From Operating Activities -$19.57M -$4.347M
YoY Change 350.13% 105.76%
INVESTING ACTIVITIES
Capital Expenditures $4.209M $18.13K
YoY Change 23114.38% 1378.87%
Acquisitions
YoY Change
Other Investing Activities $23.44M $6.600M
YoY Change 255.15%
Cash From Investing Activities $19.17M $6.563M
YoY Change 192.01% -154674.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $34.18M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 34.42M 96.71K
YoY Change 35488.8% -99.24%
NET CHANGE
Cash From Operating Activities -19.57M -4.347M
Cash From Investing Activities 19.17M 6.563M
Cash From Financing Activities 34.42M 96.71K
Net Change In Cash 34.02M 2.313M
YoY Change 1370.9% -78.15%
FREE CASH FLOW
Cash From Operating Activities -$19.57M -$4.347M
Capital Expenditures $4.209M $18.13K
Free Cash Flow -$23.78M -$4.366M
YoY Change 444.68% 106.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-32435
CY2020Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3918084
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1218351
CY2021Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-92506
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
106001
CY2021Q1 alt Retirement Of Common Sock In Exchange For Common Stock Warrant
RetirementOfCommonSockInExchangeForCommonStockWarrant
-17200000
CY2021Q1 alt Issuance Of Common Stock Warrant In Exchange For Retirement Of Common Stock
IssuanceOfCommonStockWarrantInExchangeForRetirementOfCommonStock
17200000
CY2021Q1 alt Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
10000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
45520146
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
41896617
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-14864108
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-3885649
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
880000
CY2020Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1750000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1218351
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
214921
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
74298
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
73356
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-33376
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-24939
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
191226
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
973557
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4200624
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
214893
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-194050
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
911397
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2189903
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1112718
CY2021Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
135274
CY2020Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
3360633
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19569160
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4347401
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
30912000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
13700000
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
7476074
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
7099263
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4208790
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18131
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
62041
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
19390
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19165095
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6563216
CY2021Q1 alt Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
-134413
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
39974
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34178231
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
106001
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
56739
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34418645
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
96713
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
34014580
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2312528
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8996860
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11309388
CY2021Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
17200000
CY2020Q4 alt Assets Or Liabilities Measured At Fair Value On Non Recurring Basis
AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis
0
CY2021Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:6.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company&#8217;s business, financial condition, and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on the Company&#8217;s estimates and assumptions and determined that there was not a material impact to the Company&#8217;s unaudited consolidated financial statements as of and for the three months ended March&#160;31, 2021. However, actual results could differ from those estimates and there may be changes to the Company&#8217;s estimates in future periods.</p>
CY2021Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q1 alt Assets Or Liabilities Measured At Fair Value On Non Recurring Basis
AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis
0
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
76573986
CY2021Q1 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
782
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
76574768
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
100009912
CY2020Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-4354
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
100005558
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q1 alt Economic Conditional Incentive Grants
EconomicConditionalIncentiveGrants
250000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1468124
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1824840
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.35
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6958163
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2655731
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1760111
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1598811
CY2021Q1 us-gaap Depreciation
Depreciation
67658
CY2020Q1 us-gaap Depreciation
Depreciation
59505
CY2021Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1231828
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
771548
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
460280
CY2021Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
13650795
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1169787
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
764908
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
404879
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
13588754
CY2021Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P12Y3M18D
CY2021Q1 alt Non Cancellable Lease Maturity Period
NonCancellableLeaseMaturityPeriod
2022-12
CY2021Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
130138
CY2020Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
87599
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
117354
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
95714
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1739559
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.073
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.073
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
612212
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1350194
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1182658
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2351599
CY2021Q1 us-gaap Interest Payable Current
InterestPayableCurrent
13744
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
13016
CY2021Q1 alt Accrued Research And Development
AccruedResearchAndDevelopment
7211778
CY2020Q4 alt Accrued Research And Development
AccruedResearchAndDevelopment
7316876
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
365504
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
356716
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19753
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19753
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9405649
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11408154
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
5390000
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
2750000
CY2021Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
6270000
CY2020Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
4500000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1374055
CY2020Q4 alt Economic Conditional Incentive Grants
EconomicConditionalIncentiveGrants
250000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
95383
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
110319
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1719438
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1828443
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1777611
CY2021Q1 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
1000000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2293367
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
773781
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1519586
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.11
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2776191
CY2021Q1 alt Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageExercisePrice
9.51
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y
CY2021Q1 alt Number Of Warrants Exercised For Conversion Of Securities
NumberOfWarrantsExercisedForConversionOfSecurities
1420
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2021Q1 alt Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm
P6Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16651695
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7855753
CY2021Q1 alt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingIntrinsicValue
8795942
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1218351
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
214921
CY2020Q1 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
3200000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-21-028166-index-headers.html Edgar Link pending
0001564590-21-028166-index.html Edgar Link pending
0001564590-21-028166.txt Edgar Link pending
0001564590-21-028166-xbrl.zip Edgar Link pending
alt-10q_20210331.htm Edgar Link pending
alt-20210331.xml Edgar Link completed
alt-20210331.xsd Edgar Link pending
alt-20210331_cal.xml Edgar Link unprocessable
alt-20210331_def.xml Edgar Link unprocessable
alt-20210331_lab.xml Edgar Link unprocessable
alt-20210331_pre.xml Edgar Link unprocessable
alt-ex101_6.htm Edgar Link pending
alt-ex102_226.htm Edgar Link pending
alt-ex311_11.htm Edgar Link pending
alt-ex312_10.htm Edgar Link pending
alt-ex321_7.htm Edgar Link pending
alt-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gkiizvlofxze000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending